-
公开(公告)号:US20100099610A1
公开(公告)日:2010-04-22
申请号:US12527247
申请日:2008-02-22
申请人: Sean Hu , Xao Zin , Wang Jianhua , Chihchuan Chang , Leif Nørskov-Lauritsen , Jing Su
发明人: Sean Hu , Xao Zin , Wang Jianhua , Chihchuan Chang , Leif Nørskov-Lauritsen , Jing Su
CPC分类号: C12N9/1044
摘要: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.
摘要翻译: 提供了来自链霉菌(Streptoverticillium ladakanum)的转谷氨酰胺酶的变体,其变体对人生长激素的Gln-141具有改善的选择性。
-
公开(公告)号:US20100087371A1
公开(公告)日:2010-04-08
申请号:US12527451
申请日:2008-02-22
申请人: Sean Hu , Zhao Xin , Wang Jianhua , Chihchuan Chang , Leif Nørskov-Lauritsen , Jing Su
发明人: Sean Hu , Zhao Xin , Wang Jianhua , Chihchuan Chang , Leif Nørskov-Lauritsen , Jing Su
CPC分类号: C12N9/1044
摘要: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.
-
公开(公告)号:US20240228506A1
公开(公告)日:2024-07-11
申请号:US18556222
申请日:2022-04-21
申请人: Erin F. DiMauro , Xavier Fradera , Peter H. Fuller , Min Lu , Joey L. Methot , Matthew J. Mitcheltree , Andrew J. Musacchio , Phieng Siliphaivanh , Jing Su , Merck Sharp & Dohme LLC
发明人: Erin F. DiMauro , Xavier Fradera , Peter H. Fuller , Min Lu , Joey L. Methot , Matthew J. Mitcheltree , Andrew J. Musacchio , Phieng Siliphaivanh , Jing Su
IPC分类号: C07D491/18 , A61K31/439 , A61K31/4545 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/529 , C07D471/08 , C07D519/00
CPC分类号: C07D491/18 , A61K31/439 , A61K31/4545 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/529 , C07D471/08 , C07D519/00
摘要: Described herein are compounds of Formula II, or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
-
公开(公告)号:US20230322785A1
公开(公告)日:2023-10-12
申请号:US18015387
申请日:2022-07-21
申请人: Christopher W. BOYCE , Thomas H. GRAHAM , Andrew J. HOOVER , Xianhai HUANG , Rognze KUANG , Jae-Hun KIM , Joseph M. KELLY , Michael Man-Chu LO , Jing SU , Dong XIAO , Xiaohong ZHU , Merck Sharp & Dohme LLC
发明人: Amjad Ali , Christopher W. Boyce , Jared N. Cumming , Duane DeMong , Thomas H. Graham , Subrahmanyam Gudipati , Andrew J. Hoover , Xianhai Huang , Rongze Kuang , Jae-Hun Kim , Joseph M. Kelly , Yeon-Hee Lim , Michael Man-Chu Lo , Jesus Moreno , Jing Su , Heping Wu , Dong Xiao , Younong Yu , Xiaohong Zhu
IPC分类号: C07D487/04 , C07K16/28 , A61P35/00
CPC分类号: C07D487/04 , A61P35/00 , C07K16/2896
摘要: The present invention provides compounds of the structural Formula (I) and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
-
公开(公告)号:US20180290987A1
公开(公告)日:2018-10-11
申请号:US15766395
申请日:2016-10-17
申请人: Mihir B. MANDAL , David B. OLSEN , Jing SU , Lihu YANG , Katherine YOUNG , Takao SUZUKI , Lanying YOU , Merck Sharp & Dohme Corp.
发明人: Mihir B. Mandal , David B. Olsen , Jing Su , Lihu Yang , Katherine Young , Takao Suzuki , Lanying You
IPC分类号: C07D263/20 , C07D471/04 , C07D413/10 , C07D417/10 , C07D413/04 , C07D487/04 , C07D413/06 , C07D417/14 , C07D413/14 , A61K31/421 , A61K31/437 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/506 , A61K31/553 , A61K31/4985 , A61K31/541 , A61K31/5377 , A61K45/06
摘要: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
-
公开(公告)号:US08326914B2
公开(公告)日:2012-12-04
申请号:US13112540
申请日:2011-05-20
申请人: Danny Lange , Barbara Nelson , Jing Su , James E. White
发明人: Danny Lange , Barbara Nelson , Jing Su , James E. White
IPC分类号: G06F15/16 , G06F15/173
CPC分类号: H04L67/125 , H04L63/0209 , H04L63/10 , H04L63/1408 , H04L67/28 , H04L67/2823 , H04L67/34
摘要: In one aspect, a network system includes a user interface which allows a user to interact with the network system. An agent server is coupled to the user interface. The agent server manages the operation of the network system. Furthermore, the agent server in conjunction with the user interface is operable to create or modify an agent in response to interaction by the user. In another aspect, a network system includes an agent server which manages the operation of the network system. An agent is operable to utilize a service within the network system. A service wrapper, associated with the service, cooperates with the agent server to mediate interaction between the service and the agent.
摘要翻译: 一方面,网络系统包括允许用户与网络系统交互的用户界面。 代理服务器耦合到用户界面。 代理服务器管理网络系统的操作。 此外,代理服务器与用户界面一起可操作以响应于用户的交互来创建或修改代理。 在另一方面,网络系统包括管理网络系统的操作的代理服务器。 代理可操作以利用网络系统内的服务。 与服务相关联的服务包装器与代理服务器协作来调解服务和代理之间的交互。
-
公开(公告)号:US20120172303A1
公开(公告)日:2012-07-05
申请号:US13389180
申请日:2010-08-06
申请人: Nils Langeland Johansen , Henrik Sune Andersen , Jens Buchardt , Carsten Behrens , Leif Norskov-Lauritsen , Jing Su
发明人: Nils Langeland Johansen , Henrik Sune Andersen , Jens Buchardt , Carsten Behrens , Leif Norskov-Lauritsen , Jing Su
CPC分类号: A61K47/64 , A61K47/54 , A61K47/542 , A61K47/543 , A61K47/545 , A61K47/60
摘要: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
摘要翻译: 本发明涉及针对皮下给药优化的多肽化合物,例如具有提供与白蛋白非共价结合的接头的生长激素缀合物。
-
公开(公告)号:US20120117298A1
公开(公告)日:2012-05-10
申请号:US12942045
申请日:2010-11-09
申请人: Adin Scannell , Timothy Smith , Vivek Lakshmanan , David Scannell , Kannan Vijayan , Jing Su
发明人: Adin Scannell , Timothy Smith , Vivek Lakshmanan , David Scannell , Kannan Vijayan , Jing Su
IPC分类号: G06F12/02
CPC分类号: G06F12/08 , G06F9/45558 , G06F9/5016 , G06F12/12 , G06F2009/45583 , G06F2212/152 , G06F2212/254
摘要: A method and system manages memory in a network of virtual machines, including a copy of a master virtual machine (VM) memory system, the copy accessible to a memory server. The method includes determining whether a memory page requested by a clone VM memory system is fetchable from the memory server, the clone VM memory system hosted in a host memory system; if the memory page is fetchable from the memory server, fetching the memory page from the memory server; determining whether there is sufficient space in the host memory system to load the memory page; if there is insufficient space in the host memory system, evicting a selected memory page from the host memory system; and loading the memory page into the host memory system and the clone VM memory system.
摘要翻译: 一种方法和系统管理虚拟机网络中的存储器,包括主虚拟机(VM)存储器系统的副本,存储器服务器可访问的副本。 所述方法包括确定克隆VM存储器系统请求的存储器页是否可从存储器服务器获取,所述存储器存储系统托管在主存储器系统中; 如果从存储器服务器获取存储器页面,则从存储器服务器获取存储器页面; 确定主机存储器系统中是否有足够的空间来加载存储器页面; 如果在主机存储器系统中没有足够的空间,则从主机存储器系统中驱逐选定的存储器页面; 并将内存页面加载到主机内存系统和克隆VM内存系统中。
-
公开(公告)号:US20080064630A1
公开(公告)日:2008-03-13
申请号:US11578629
申请日:2005-04-14
申请人: Niels Blume , Jing Su , Kjeld Madsen , Nils Johansen , Lars Iversen
发明人: Niels Blume , Jing Su , Kjeld Madsen , Nils Johansen , Lars Iversen
CPC分类号: C12N15/62 , C07K2319/31
摘要: Fusion protein comprising a protein to be fused, e.g. a therapeutic protein fused to the C-terminal of osteogenic growth peptide (OGP). The fusion proteins have a prolonged circulation time.
摘要翻译: 包含待融合的蛋白质的融合蛋白,例如 与成骨生长肽(OGP)的C端融合的治疗性蛋白质。 融合蛋白具有延长的循环时间。
-
10.
公开(公告)号:US20070066630A1
公开(公告)日:2007-03-22
申请号:US11600216
申请日:2006-11-15
申请人: Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying Huang , Robert Aslanian , Brian McKittrick , Sylvia Degrado
发明人: Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying Huang , Robert Aslanian , Brian McKittrick , Sylvia Degrado
IPC分类号: A61K31/519 , C07D491/02
CPC分类号: C07D491/052
摘要: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译: 本发明提供式(I)化合物及其药学上可接受的盐,溶剂合物,酯和互变异构体,其中:Q选自:L选自:包含一种或多种 式(I)化合物和使用式(I)化合物的方法。
-
-
-
-
-
-
-
-
-